- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01641926
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
July 27, 2018 updated by: Merck Sharp & Dohme LLC
A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been treated with interferon.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
402
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be able to adhere to dose and visit schedules
- ≥ 40 kg
- Hepatitis B surface antigen (HBsAg) positive for at least 6 months
- Anti-HBs negative
- Female participants of childbearing potential must agree to use an acceptable
method of contraception from at least 2 weeks prior to Day 1 and continue until at least 1 month after last dose of study drug
Inclusion Criteria for HBeAg(+) participants:
- HBeAg(+)
- Anti-HBe(-)
Inclusion Criteria for HBeAg(-) participants:
- HBeAg(-)
- Anti-HBe(+)
Exclusion Criteria:
- Co-infection with the human immunodeficiency virus (HIV) or hepatitis C or hepatitis D virus
- Prior treatment with interferon for hepatitis B
- Use of nucleoside/nucleotide analogues within 6 months of the screening visit or at any time during the study
- Use of any investigational drug within 30 days of the screening visit
- Prior treatment with herbal remedies with known hepatotoxicity. All herbal remedies used for hepatitis B treatment must be discontinued before Day 1
- Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
- Diabetic and/or hypertensive with clinically significant ocular examination findings
- History of stroke or transient ischemic attack
- Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], celiac disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis requiring oral or injected treatment, or symptomatic thyroid disorder)
- Chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis)
- Current or history of any clinically significant cardiac abnormalities/dysfunction
- Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial
- Myelodysplastic syndromes
- Organ transplants (including hematopoietic stem cell transplants) other than cornea and hair
- Pregnant or nursing, or intending to become pregnant during the trial period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HBeAg(+) PEG-Intron
HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
|
PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
Other Names:
|
Active Comparator: HBeAg(+) PEGASYS
HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
|
PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
Other Names:
|
Experimental: HBeAg(-) PEG-Intron
HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
|
PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
Other Names:
|
Active Comparator: HBeAG(-) PEGASYS
HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
|
PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment
Time Frame: FU Week 24 (Study Week 72)
|
Blood samples were drawn to assess the participant's seroconversion status at Follow-up (FU) Week 24.
HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.
|
FU Week 24 (Study Week 72)
|
Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment
Time Frame: FU Week 24 (Study Week 72)
|
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(-) participants.
The percentage of HBeAg(-) participants with HBV DNA <2000 IU/mL at 24 weeks post-treatment was reported.
|
FU Week 24 (Study Week 72)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
Time Frame: FU Week 24 (Study Week 72)
|
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(+)participants.
The percentage of HBeAg(+) participants with HBV DNA <2000 IU/mL at 24 weeks post-treatment was reported.
|
FU Week 24 (Study Week 72)
|
Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment
Time Frame: FU Week 24 (Study Week 72)
|
ALT normalization is a desired goal of HBV treatment, which is defined as having abnormal ALT levels at baseline and subsequently normal ALT levels after receiving treatment, where normal is defined as ≤ 1x the upper limit of normal (ULN).
The percentage of HBeAg(+) and HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment was reported.
|
FU Week 24 (Study Week 72)
|
Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
Time Frame: FU Week 24 (Study Week 72)
|
HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.
HBV DNA levels in blood were measured by the Roche COBAS TaqMan HBV-(High Pure System Assay).
The percentage of HBeAg(+) participants with the combined response of achieving both HBeAg conversion and HBV DNA levels <2000 IU/mL at 24 weeks post-treatment was reported.
|
FU Week 24 (Study Week 72)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Merck Sharp & Dohme LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 26, 2012
Primary Completion (Actual)
January 21, 2016
Study Completion (Actual)
January 21, 2016
Study Registration Dates
First Submitted
July 11, 2012
First Submitted That Met QC Criteria
July 16, 2012
First Posted (Estimate)
July 17, 2012
Study Record Updates
Last Update Posted (Actual)
August 27, 2018
Last Update Submitted That Met QC Criteria
July 27, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Peginterferon alfa-2a
- Interferon alpha-2
- Peginterferon alfa-2b
Other Study ID Numbers
- P08450
- MK-4031-376 (Other Identifier: Merck study number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
Clinical Trials on PEG-Intron™
-
Merck Sharp & Dohme LLCCompletedHIV Infections | AIDS
-
Brooke Army Medical CenterT.R.U.E. Research FoundationCompleted
-
University of PittsburghNational Cancer Institute (NCI)Completed
-
The Cleveland ClinicCompleted
-
Fundación de Investigación Biomédica - Hospital...Haematology Service,Unknown
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Diabetes and Digestive and...Schering-Plough; Ortho Biotech Clinical Affairs, L.L.C.CompletedHepatitis CUnited States
-
Ain Shams UniversitySchering-Plough; Tempus Labs; Fulbright; International Society for Infectious DiseasesCompleted
-
The Methodist Hospital Research InstituteSchering-PloughTerminatedCarcinoma, Renal CellUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedRecurrence | Hematological NeoplasmsChina